Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

February 12, 2021 by Novian Health

February 12, 2021
Contact: Eugene Bajorinas, (312) 266-7200
E-mail: info@novianhealth.com

Series B Financing will enable European commercialization and U.S. market approval of Laser Therapy System

CHICAGO – Novian Health, developer of Novilase® Breast Therapy, announced today that it has been selected to present at the Cavendish Global Summit on February 25th.  This exclusive virtual opportunity invites members to meet and hear from the latest field experts and select Cavendish Innovation Partners (https://cavendishglobal.com/summit-series/10).

“We are excited to be part of the Cavendish community,” said Henry “Chip” Appelbaum, Novian Health’s President and CEO. “With our laser technology, we hope to improve the treatment of early-stage breast cancer for women and make it more effective and less traumatic than surgery.  We are making significant progress in that direction, having developed the only ablation device to receive European market approval to treat breast cancer.  In the U.S., FDA approved an expedited pivotal trial to support market approval.”  The Series B will allow the company to complete the trial for U.S. clearance, launch European commercial operations, bring forth a second indication to market and evaluate the immunotherapeutic benefit of laser ablation.

About Cavendish

Cavendish summits convene their community once a month, hosting critical discussions, and showcasing groundbreaking discovers and innovations.  Companies are reviewed in a rigorous process that examines the companies’ technological innovation, health impact and management strength.  Cavendish is a peer-to-peer community of groundbreaking innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key experts and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformational impact.

About Novilase

Novilase is a laser-based, minimally invasive device for destroying tumors. It provides an alternative to conventional surgery while preserving the patient’s options for additional procedures or adjunctive therapies. The image-guided outpatient procedure does not require general anesthetic or a hospital stay.

About Novian Health

Novian Health Inc., based in Chicago with a subsidiary in Evry, France, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy.  Developed as an alternative to surgery, the Company’s image-guided treatment of breast tumors is the first application of the technology, with the potential for Novilase to treat tumors elsewhere in the body. Novian Health has received a CE Mark for the focal destruction of cancerous and benign breast tumors, as well as U.S. FDA 510(k) clearance for the treatment of benign breast tumors. For more information, call (312) 266-7200 or access www.novianhealth.com.

Related Posts

  • Novian Health Presents at William Blair Private Conference
  • Novian Health Announces Agreement with Rose Medical Center in Denver
  • Novian Health Announces Agreement with Tower Radiology Center in Tampa Bay
  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)
  • Novian Health Presents at the “2nd Annual Venture Connections: A Frost & Sullivan Executive Symposium

Filed Under: Press Release 2021

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by